Ashland injectable pharmaceutical excipient accepted into FDA Novel Excipient Review Pilot Program

WILMINGTON, Del., Oct. 31, 2022 (GLOBE NEWSWIRE) announced the United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research Office of New Drugs has accepted Ashland Viatel™ bioresorbable mPEG-PDLLA pharmaceutical excipient in the review cycle of the FDA Novel Excipient Review Pilot Program.

WILMINGTON, Del., Oct. 31, 2022 (GLOBE NEWSWIRE) announced the United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research Office of New Drugs has accepted Ashland Viatel™ bioresorbable mPEG-PDLLA pharmaceutical excipient in the review cycle of the FDA Novel Excipient Review Pilot Program.